Financial News
Latest News about IONS
Recent news which mentions IONS
Biogen Announces Additional Cost Cutting Initiatives, Chops Certain Stroke, Gene Therapy Programs
April 25, 2023
From Benzinga
3 Biotech Stocks to Sell Before They’re 6 Feet Under
April 24, 2023
From InvestorPlace
AstraZeneca, Ionis Unveil Complete Phase 3 Data For ATTR Candidate, Says Drug Halts Disease Progression
April 24, 2023
From Benzinga
Could This Rare-Disease Drug Candidate Become a Blockbuster?
April 19, 2023
From Motley Fool
From Benzinga
AstraZeneca-Ionis Partnered Rare Disease Drug Data Shows Sustained Benefit; Drug Under FDA Review
March 27, 2023
From Benzinga
FDA Adcomm Says Benefit-Risk Profile Favor Biogen's Tofersen For Inherited Neuro Disorder
March 23, 2023
From Benzinga
From Benzinga
Wall Street predicts approval for another ALS drug
March 21, 2023
From MarketWatch
Biogen Triumphs In Legal Battle Regarding Tecfidera, Delaying EU Generic Erosion For Another Year
March 16, 2023
From Benzinga
Analyst Says Ionis' Additional Hereditary Angioedema Study Data Supports 'Highly Competitive Profile'
February 21, 2023
Tickers
IONS
From Benzinga
EXAS Nears Key Buy Signal in Active Biotech ETF ARKG
January 11, 2023
From ETF Trends
Benzinga's Top Ratings Upgrades, Downgrades For December 21, 2022
December 21, 2022
From Benzinga
Ionis Pharmaceuticals Earnings Perspective: Return On Capital Employed
December 13, 2022
Tickers
IONS
From Benzinga
Gene Deal Adds New Dimension to Biotech ETF SBIO
November 16, 2022
From ETF Trends
4 Analysts Have This to Say About Ionis Pharmaceuticals
November 10, 2022
Tickers
IONS
From Benzinga
From Benzinga
Ionis Regains Rights To Thrombosis Candidate From Bayer
November 04, 2022
From Benzinga
3 Biotech Stocks to Sell in October
September 29, 2022
From InvestorPlace
AstraZeneca Pulls Plug On Ionis Pharma-Partnered Cholesterol Med
September 23, 2022
From Benzinga
This Stock Has Delivered a Gain of 100% Over the Past 3 Months. Can You Still Buy?
September 12, 2022
From Motley Fool
There's 'Outsized' Risk-Reward For This Biotech, Morgan Stanley Says, Predicting Shares Could Grow More Than 30%
September 09, 2022
Tickers
IONS
From Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022
September 09, 2022
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
